Kronos Bio Expands Clinical Team with the Appointment of Zung To as Vice President, Clinical Operations
San Mateo, Calif., and Cambridge, Mass., May 19, 2020 – Kronos Bio, Inc., dedicated to drugging transcriptional regulatory networks in cancer, announced expansion to its clinical development team with the appointment of Zung To as Vice President, Clinical Operations. In this new position, Mr. To will assist in defining developmental strategy, guiding clinical protocol design and study conduct.. He will report to Jorge DiMartino M.D., Ph.D., the company’s Chief Medical Officer and Executive Vice President, Clinical Development.
“We are very pleased to continue to attract cross functional innovators in biotechnology as we prepare to become a clinical stage company,” said Dr. DiMartino. “Zung will play a vital role in overseeing our clinical operations and be instrumental as our product candidates move through stages of development.”
Mr. To has over 25 years of biotechnology drug development experience with a focus on innovative clinical operations. He joins Kronos from Jazz Pharmaceuticals where, as Vice President of Development Operations, he managed clinical operations, data management, and vendor alliance management, focused on neuroscience and oncology. Prior to that, Mr. To was Senior Director of Clinical Operations and BioOncology Therapeutic Area Head at Genentech where he oversaw clinical operations for the Early Development oncology portfolio.
Mr. To received a B.S. in biological sciences from the University of California, Davis.
About Kronos Bio, Inc.
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription.
# # #
Dr Yasir Al-Wakeel
CFO & Head of Corporate Development